Bausch + Lomb (BLCO) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Bausch + Lomb (BLCO) right now is Margin and EBITDA expansion: After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Revenue (TTM) is ~$5.2B. If that keeps playing out, the setup is favourable; the risk to it is the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. No one can predict where BLCO trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Bausch + Lomb (BLCO) higher?
1. Margin and EBITDA expansion
After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Q1 2026 adjusted EBITDA rose roughly 59% year over year, and management raised full-year adjusted EBITDA guidance toward the $1.01 to $1.06 billion range, signaling that the profitability inflection may be durable rather than a one-off.
2. Pharmaceuticals and MIEBO ramp
The pharmaceuticals segment posted the fastest growth in early 2026, led by the dry-eye drug MIEBO and international brands. Dry-eye disease is a large, underserved market, and continued MIEBO uptake gives the company a branded growth engine to offset slower U.S. generics.
3. Secular eye-care demand and surgical recovery
An aging global population, rising rates of myopia and growing cataract-surgery volumes support steady demand across contact lenses and surgical devices. The enVista intraocular-lens franchise returned to full production and reached pre-recall sales levels by late 2025, restoring its role in the premium IOL segment.
4. Separation catalyst from Bausch Health
Bausch Health still owns the large majority of BLCO and has explored both a spin-off and a sale for years. A clean separation, if it clears solvency hurdles, could remove the control discount and let BLCO trade closer to eye-care peers, though timing remains uncertain.
What could weigh on BLCO?
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
Where BLCO trades today
A forecast starts from where the stock actually is. These are BLCO's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for BLCO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a BLCO forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BLCO guide and whether BLCO is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BLCO outlook
The bottom line: what is driving Bausch + Lomb (BLCO) is Margin and EBITDA expansion, with revenue (ttm) at ~$5.2B. If that keeps playing out the setup is favourable; the risk is the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. No one can predict the price, so treat any BLCO forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around BLCO with Walnut
Use Bausch + Lomb as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Bausch + Lomb (BLCO)?
+
No one can reliably predict where BLCO will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Bausch + Lomb higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BLCO higher?
+
The main growth drivers are Margin and EBITDA expansion; Pharmaceuticals and MIEBO ramp; Secular eye-care demand and surgical recovery. Whether they play out is the real question, not a guaranteed path.
What are the risks to BLCO?
+
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
Will BLCO stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Bausch + Lomb's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BLCO a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BLCO "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.